Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MJNA Bloomberg News Featured, Medical Marijuana, Inc. $MJNA CEO Discussing Growth of CBD Market in Brazil https://www.prnewswire.com/news-releases/bloomberg-news-features-medical-marijuana-inc-ceo-discussing-growth-of-cbd-market-in-brazil-300833623.html
Aurora Cannabis (NYSE: ACB) ..."signed a royalty-bearing commercial licensing agreement with EnWave Corporation, providing Aurora with the exclusive rights to EnWave's patented Radiant Energy Vacuum (REV™) drying technology and has also given $10 million in capital as strategic equity investment. Edmonton-based Aurora said it plans to incorporate EnWave's so-called radiant energy vacuum, or REV, technology into the production process for cannabis materials in the European Union and elsewhere by purchasing EnWave's REV machines and technology."
https://ih.advfn.com/stock-market/NYSE/aurora-cannabis-inc-ACB/stock-news/79820947/ancillary-canna-stock-to-benefit-from-industry-gro
ACB
.
$MJNA has the sauce!
$NIO nice breakout
NYSE Nio Inc. $NIO NIO NYSE IPO Highlight https://vimeo.com/298211788
TSX:OGI~OGRMF~"OrganiGram Holdings: CA$30.7 million in gross recreational sales"......
https://www.fool.com/investing/2019/04/30/3-pot-stocks-selling-the-most-recreational-marijua.aspx
.
$CHK Chesapeake Energy HEATING UP WEEEEEEEeeeeeeee
$NIO SMART MONEY ACCUMULATING DOWN HERE!
Revenues up over 3000% this quarter compared to the September 2018 quarter. Financing set up for the massive growth next year. Keep watching, the news will be very significant. @mlinehc #timetogetexcited
— M Line Holdings, Inc. $MLHC (@mlinehc) December 21, 2018
$INSY nice buy here
$PJET - Dissolved oxygen water crafted to increase your high by 20% for drinking and bong water. Also partnerships with $PURA for thier license patent tech cbd extractions process makes this cheap plus merger an excellent buy. In the trips for now
#DMAN: GROWING HOME GROWN...:-} 0.007
1.79 bil Float $ILST Merger lotto 0001/2 CEO said filings then news (904) 207-6502
INTK - keep mold and mildew out of the grow room - INTK company intents to uplist to a more senior exchange.
Under a penny patent tech
Canntab Therapeutics; two MMJ DEVELOPMENTS and updated news.
Canntab Therapeutics Limited (CSE: PILL) (“Canntab” or the “Company”) is pleased to announce two recent developments: (i) an update on its application for a Dealer’s License with Health Canada; and (ii) its Australian joint venture partner has obtained a license to import medical cannabis products.
Application for a Dealer’s License with Health Canada.
The Company has engaged an experienced consultant for the purposes of finalizing and submitting an application to obtain a Health Canada Dealer’s License (“Dealer’s License”) under the Controlled Drugs and Substances Act (“CDSA”) and its associated regulations. The Dealer’s License will allow Canntab to continue with the development of its proprietary products including the XR Tablet and will allow Canntab to manufacture and sell the products in Canada and elsewhere.
Further, the Dealer’s License, when combined with an export permit that the Company intends to apply for after receiving its Dealer’s License, will allow the Company to export its proprietary Extended Release Tablet (“XR Tablet”) to certain international markets. Trevor Moore, a veteran of the Canadian medical cannabis industry, has been retained by the Company to assist in preparing its application for a Dealer’s License. Mr. Moore has previously helped two Licensed Producers obtain their licenses, and is an expert in the areas of quality assurance, regulatory compliance and government relations.
Australian Joint Venture
Canntab entered into a joint venture agreement with Queensland Bauxite Ltd. (“QBL”) and its wholly owned subsidiary Vitacan Pty Ltd. (“Vitacan”) (the “Joint Venture Agreement”) pursuant to the Joint Venture Agreement the parties shall manufacture, distribute and sell Canntab’s proprietary products including its XR cannabis tablets in Australia. The Joint Venture may extend to other territories in Asia. Pursuant to the Joint Venture Vitacan has agreed to contribute the
first $1,000,000 US of capital required by the Joint Venture.
“We are very excited to expand Canntab’s business to the Australian market which is a very progressive market for the development and sale of marijuana and marijuana products,” said Jeffrey Renwick, the CEO of Canntab.
Australian JV Partner Obtains Import License
The Company’s Australian joint venture partner, Queensland Bauxite Ltd. (“Queensland Bauxite”) and its subsidiary, Medical Cannabis Limited (“MCL”), recently announced that MCL entered into a binding memorandum of understanding (“MOU”) with Burleigh Heads Cannabis (“BHC”), which holds an import license issued by the Australian Office of Drug Control. Under the terms of the MOU, BHC will provide the import and storage services for MCL’s international medical cannabis products.
About Queensland Bauxite
Queensland Bauxite Ltd is an Australian listed company focused on the exploration and development of its bauxite tenements in Queensland and New South Wales. The Company’s lead project is the South Johnstone Bauxite Deposit in northern Queensland which has rail running through the project area and is approximately 15-24 kilometres from the nearest deep water port. The Company intends to become a bauxite producer with a focus on commencing production at South Johnstone as early as possible. The Company also pursues additional investment opportunities, and has acquired a 55% shareholding in Medical Cannabis Limited, an Australian leader in the hemp and Cannabis industries.
The subsidiary of QBL is going from one milestone to another - ones we see the revenue start coming, this will gain the value of QBL.
Considering the relative low valuation today, the leverage will be very strong one`s revenues are increasing. I reckon the first quarterly report, will not be so strong revenue; it will take some months to get the hemp wellknown within the mainstream media and awareness.
Within the second quaerterly report, the hemp revenue will be larger. It will also show the first revenues from the first sales of MMJ medics.
We have exciting times ahead of us - to be taking part of this historic event is a blessing. Hemp and MMJ will change many peoples lifes.
See updated news on board.
See QBL-board and website. https://www.queenslandbauxite.com/
There is a lot going on now in this company.
Hemp Gazette on MMJ and EXCLUSIVE IMPORT from Canada.
Australian Company Seeks To Import Medical Cannabis Tablets.
QBL subsidiary MCL has inked a deal with Canada’s Canntab Therapeutics to bring Canntab XR tablets into Australia. The tablets are designed to deliver cannabinoids over a number of hours and have varying levels of THC and/or CBD. The company says the tablets take the guesswork out of cannabis medicines, which will make doctors more comfortable in prescribing them.
The enthusiastic announcement from QBL regarding the joint venture agreement claims Canntab is a “game-changing” medicine. “Everyone knows someone who could benefit from this new technology,” said Pnina Feldman, QBL Executive Chairperson. Canntab CEO Jeff Renwick says the deal enables the company to bring a significant advancement in cannabis-based medicines to Australia.
The QBL subsidiary MCL will now need to work towards securing the necessary approvals in order to import the product into Australia, which it is confident in obtaining. The company will also have first rights to distribute the products throughout Asia.
“We believe that the patents filed and pending protects key features of our IP, and positions Canntab to be the definitive Cannabis delivery method of choice among the established medical professions and ever- expanding number of Australians using cannabis every day for medical purposes, and an even greater number who would find benefits from its use,” states the announcement.
Each of Canntab’s five products is available in different dosage levels (2.5mg, 5mg, and 10mg) and in instant and stable extended release. The extended-release products are designed to release the active pharmaceutical ingredient at a predetermined rate in order to maintain a constant concentration over a specific period of time; which could be up to 18 hours.
Four of the products contain THC or THC and CBD, while Canntab “Yellow” tablets only contain CBD. It’s been a busy couple of weeks for Medical Cannabis Limited. Late last month we reported it had teamed up with Australia’s Algae.Tec Ltd (ASX:AEB) in a project researching cannabis-based veterinary medications.
ABOUT US
Hemp Gazette is a medicinal marijuana and industrial hemp information website. Based in Australia, we publish the latest breaking legal, medical and business news, research and industry reports from around the world.
See QBL-board and website; https://www.queenslandbauxite.com/
Aurora Cannabis Inc (OTCMKTS:ACBFF) Rides Growth Strategy https://oracledispatch.com/2018/04/23/aurora-cannabis-inc-otcmktsacbff-rides-growth-strategy/
Strong MMJ NEWS TONIGHT - QBL will likely continue rise in sharevalue next week as well. With a 55% of QBLs subsidiary shares, the listing of it`s subsidiary will increase it`s 30% rice last week.
MMJ Legend Hamish Sutherland; on CannTab Board as ADVISOR.
The CannTab management and Advisory Board is impressing, we highlight here one of the most famous within MMJ INDUSTRY.
Hamish is one of a select few who has real experience in building a successful cannabis company, as the founding COO for Bedrocan Canada, delivering over $400-million in returns for shareholders. He was responsible for the first legal international transfer of live cannabis plant material from Holland to Canada, and was accountable for the “greenfield” construction and commissioning of Bedrocan’s state-of-the-art automated facility, which was acquired by Tweed (now Canopy Growth) to become the leading cannabis company in Canada. Hamish is a Professional Engineer in Ontario, earned his MBA from Schulich, and is the active Chair of the Little Geeks Foundation. He loves basketball, sailing and helping youth achieve their potential.
Take a look at the trackrecord of the team behind CannTab - we are talking about established professionals at the highest level. The more I see of QBLs subsidiary and there businessmodel, I feel confident of a winning team, products and the whole concept.
VITAHEMP has released its "Black Label" Premium range of Hemp Seed Oil soft gel capsules.
120CAPS x 750mg. Hemp Seed Oil Capsules are a wonderful plant-based alternative to conventional fish oil. Each soft gel capsule contains a rich source of EFA's (Omega 6 and 3) in a 3:1 ratio and Gamma Linolenic Acid.
If you are taking Fish Oil capsules consider this plant-based alternative. No fishy aftertaste! :) (y)
https://www.facebook.com/vitahemp/
https://vitahemp.com/product/hemp-seed-oil-capsules/
With a great distribution network, they have managed to get a major window to the public for there Products. They also sell on-line threw there e-shop on the website.
8 Products so far and more on the way - hemp will be big !
$RSII $RBIO is a easy 3 bagger from here in the near term look at this DD Folks CLICK HERE
And this chart is totally indicating a Big Bounce
#RSII: Like Minded Folks...:-} 3 Bags coming...0.0486
https://globenewswire.com/news-release/2018/01/18/1296465/0/en/Rising-Biosciences-Inc-Develops-Groundbreaking-Oral-THC-CBD-Delivery-Capsule-Cannophen-Nears-Completion-on-MMJ-Laboratory-in-Ohio.html
THC/CBD pill revolutionary...!
“We are also thrilled to announce that included in a line of medical cannabis products, the company is debuting Cannophen™, a revolutionary product we’ve been developing for some time now. Cannophen™ is an oral capsule with laboratory controlled metered dosing that can be blended in exacting ratios of THC, CBD and strain specific tirpenes. It is easily digestible and fast acting and designed for patients that do not want to smoke/vape or use off-tasting tinctures. This allows patients to take their medicine by swallowing a flavorless capsule, just like any other oral medication. We are also pleased to announce a new MMJ version of the TSW pain cream containing Cannabidiol (CBD).”
Hall adds, “There has never been any proper way to dose with the above said methods. We have developed Cannophen™ using the strictest quality and control standards and methods set forth in the pharmacy compounding industry using experienced chemists and veteran pharmacists.
$RSII $RBIO PRESS RELEASE - 03/20/2018
SANDUSKY, Ohio, March 20, 2018 (GLOBE NEWSWIRE) -- (via OTC PR WIRE) --Rising India, Inc.’s (OTC:RSII) -- Rising Biosciences, Inc., a research and development company focusing on oral and topical pharmaceuticals with strict standards set forward by the pharmaceutical compounding industry, is pleased to announce that it has launched near-term initiatives to expedite growth for long-term shareholder value.
$Before and After
$Ready For Production
$Rising BioScience's Cannophen TM
We are thrilled to announce that Rising Biosciences will also be rolling out its RBS0238 CLINICAL PEPTIDE SERUM (our scar serum) in Q2. “We could not be more excited to announce that after a recent meeting with the manufacturer of our clinical strength peptide serum, we are officially entering production phase for the product line and it will be on sale, available for national distribution, in late April/early May,” states Hall. “This means revenues, revenues and more revenues.”
“As well, we have corresponded in regards to the FDA testing procedures on our TSW pain cream and they continue to progress to what we feel will be near-term completion.”
The Company has also recently hired a seasoned chemist who will serve as Chief Chemist in-house at the Company’s Ohio Laboratory. COO Arthur Hall states, “Our Chief Chemist will be traveling to Florida to train with our staff there on overall procedures and protocol. We are thrilled to have secured talent at this level which will greatly expedite research and development on new product ideas as well as staff expertise in all of our locations.”
“As well, we have purchased analytical equipment which will allow us to do developmental testing on-site as opposed to the costly and timely procedure of shipping to an outside laboratory. The equipment is paid for and scheduled to be installed next week.”
The Company also announces updates on expansion and have entered into contracting stages with two California Producer/Processors, one of which also has operations and facilities in Arizona for manufacturing Cannophen™ and TSW pain cream with CBD/THC. A Producer/Processor grows or extracts (THC, CBD, etc.) directly from flower and also processes and manufactures MMJ products. “We anticipate this to effect a near-term multiplier regarding overall operations and potential revenues.”
“The Medical Marijuana revolution has only begun,” states Hall. “The US government recently updated content pages on the National Cancer Institute’s (an official division of the US Department of Health) website to include information about cannabis and cannabinoids.”
The new updates, implemented in January, include information indicating that cannabis and cannabinoids can kill cancer without damaging the body’s normal cells.
The National Cancer Institute states a number of facts about Antitumor activity and pain relief, among others, citing studies in mice and rats which have shown that cannabinoids may inhibit tumor growth by causing cell death, blocking cell growth, and blocking the development of blood vessels needed by tumors to grow. Laboratory and animal studies have shown that cannabinoids may be able to kill cancer cells while protecting normal cells. As well, it goes on to state that A laboratory study of cannabidiol (CBD) in human glioma cells showed that when given along with chemotherapy, CBD may make chemotherapy more effective and increase cancer cell death without harming normal cells. Studies in mouse models of cancer showed that CBD together with delta-9-THC may make chemotherapy such as temozolomide more effective.
“We are on the cusp of something fantastic here and are grateful for continued shareholder participation. We are developing life-changing products and anticipate continued shareholder value alongside assertive R&D initiatives, partnerships and acquisitions as well as both B2B and B2C sales strategies for our product lines,” concludes Hall.
Hall is planning trips to Colorado and Michigan in the coming weeks to meet with producers and processors in those markets, among others on the company’s agenda.
“Rising Biosciences Inc. along with PAO Group Inc. helping reduce the grip of opiods on America through the responsible use of cannabis”
$RSII on Twitter for LIVE company updates! www.twitter.com/risingindiausa
Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward- looking statements to reflect events or circumstances after the date of this release.
CONTACT INFO:
For Investor Inquiries:
CAL
IR@risingbiosciences.com
Photos accompanying this announcement are available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/33dc7625-1b29-4775-bdc1-e99f8549d260
http://www.globenewswire.com/NewsRoom/AttachmentNg/810f7842-955a-4d1a-aed4-fbf741c60843
Canntab;Putting the ‘Medical’in Medicinal CANNABIS
Canntab Therapeutics is bringing pharmaceutical expertise to the cannabis market through the development of its patent-pending Canntab Extended Release (XR) Tablets™. Using proprietary extended release technology previously developed by the company, Canntab is producing a safe, stable and standardized delivery method for cannabis particles (CBD and THC) that is not burdened with the negative effects associated with smoking, edibles or topicals.
The proprietary extended release technology provides lasting effects of 12 to 18 hours, making the Canntab XR Tablets™ an appealing alternative to other intake methods. The XR Tablets™ have also been designed for doses of 2.5 mg, 5.0 mg or 10.0 mg, making dosing and prescribing much more straightforward for the medical community.
Based in Markham, Ontario, the company will be expanding their operations as they move into an independent 10,000 square-foot area within the FV Pharma facility in Cobourg, Ontario. From there, the company will be producing and distributing its products.
Additionally, Canntab has also entered into a licensing agreement with Emblem Corp, a licensed producer (LP), under which Emblem will develop and market Canntab’s XR Tablets™ in Canada.
Beyond Canada, Canntab has entered into a joint venture with Vitacann, a subsidiary of Queensland Bauxite (ASX:QBL) , under which the companies will work towards the approval of sales of Canntab XR Tablets™ in Australia as well as their export to Asia.
Canntab is led by a management team with proven experience in both the pharmaceutical and capital market spaces. The company’s leaders, Jeff Renwick and Richard Goldstein, have been working with their team to develop Canntab’s proprietary technology for almost a decade and have numerous patents for unique drug formulations, making them leaders within the cannabis pharmaceutical space.
The management team is also supported by board members Vitor Fonseca and Sheldon Inwentash, both of which provide extensive insight into financial aspects and business development.
https://investingnews.com/company-profiles/ca...rapeutics/
#RSII: First Hemp then Cannabis Legalization...:-} 0.0486
Thats right Silver Harvest... One pretty Chart...
https://www.forbes.com/sites/tomangell/2018/03/26/sen-mitch-mcconnell-pushes-bill-to-legalize-hemp/#6df52696581a
With HEMP becoming Legal soon can Cannabis legalization be for behind...:-] ?
MAR 26, 2018 @ 11:36 AM
Sen. Mitch McConnell Pushes Bill To Legalize Hemp
The head of the U.S. Senate announced on Monday that he will soon be filing a bill to legalize industrial hemp and allocate federal money for cultivation of the crop.
"We all are so optimistic that industrial hemp can become sometime in the future what tobacco was in Kentucky's past," U.S. Senate Majority Leader Mitch McConnell (R-KY) said at a press conference alongside the state's agriculture commissioner.
"I will be introducing when I go back to senate a week from today," he said, legislation to "finally legalize hemp as an agricultural commodity and remove it from the list of controlled substances."
McConnell has already successfully attached language to broader legislation, such as the 2014 Farm Bill and annual spending packages, that shields state industrial hemp research programs from federal interference.
But confusion over what counts as research as well as issues related to the interstate transportation of hemp seeds has caused confusion as the Drug Enforcement Administration has in some cases sought to enforce federal laws that do not distinguish between hemp and marijuana.
A press release from McConnell's office said the new bill will not only reclassify hemp under federal law, but "will also give hemp researchers the chance to apply for competitive federal grants from the U.S. Department of Agriculture – allowing them to continue their impressive work with the support of federal research dollars."
At the event, McConnell said that "some challenges remain today between the federal government and farmers and producers in Kentucky," arguing that his new bipartisan legislation would "remove the roadblocks altogether" by "recognizing in federal statute the difference between hemp and its illicit cousin."
He added that he would soon be discussing the issue with U.S. Attorney General Jeff Sessions, an longtime vocal opponent of cannabis law reform who this year rescinded Obama-era guidance that has generally allowed state to implement their own marijuana legalization laws without federal interference.
In federal spending legislation enacted last week, Congress extended a policy rider that prevents the Justice Department from interfering with state medical cannabis laws. The bill also extends two provisions that protect state industrial hemp research programs.
Hemp can be used to make food, clothing and many other consumer goods.
McConnell, in the Monday speech, spoke about "interesting and innovative products" that are "made with Kentucky-grown hemp," such as home insulation.
"That's just one of many uses Kentuckians are finding for this versatile crop," he said.
While hemp products are legal to sell in the U.S., its cultivation is banned outside of the limited exemption for state research programs, so manufacturers must in many cases import the raw materials from other countries that do no prohibit hemp farming.
McConnell was an original cosponsor of a standalone industrial hemp bill during the 114th Congress, but it did not receive a hearing or a vote. Last year he signed onto a nonbinding resolution approved by the Senate in recognition of Hemp History week.
"Industrial hemp holds great potential to bolster the agricultural economy of the United States," the measure declared.
Sen. Rand Paul (R-KY) will be an original cosponsor of the new bill to be introduced next month, along with a bipartisan group of other senators.
#RSII:_California,_Florida,_Colorado,_Michigan,_Arizona.:-}_NATIONAL_DISTRIBUTION...:-}
https://www.risingbiosciences.org/single-post/2018/03/21/PRESS-RELEASE---03202018
https://twitter.com/risingindiausa
The Company has also recently hired a seasoned chemist who will serve as Chief Chemist in-house at the Company’s Ohio Laboratory. COO Arthur Hall states, “Our Chief Chemist will be traveling to Florida to train with our staff there on overall procedures and protocol. We are thrilled to have secured talent at this level which will greatly expedite research and development on new product ideas as well as staff expertise in all of our locations.”
Hall is planning trips to Colorado and Michigan in the coming weeks to meet with producers and processors in those markets, among others on the company’s agenda.
The Company also announces updates on expansion and have entered into contracting stages with two California Producer/Processors, one of which also has operations and facilities in Arizona for manufacturing Cannophen™ and TSW pain cream with CBD/THC. A Producer/Processor grows or extracts (THC, CBD, etc.) directly from flower and also processes and manufactures MMJ products. “We anticipate this to effect a near-term multiplier regarding overall operations and potential revenues.”
Just in case anyone is interested.
Fourth Quarter and Year-End 2017 Earnings Conference Call
March 16, 2018 • 4:30pm EDT
Dial-In Number: 1-857-232-0157
Access Code: 422095
https://ir.terratechcorp.com/ir-calendar
SYMBOL TRTCD
QBL MMJ/HEMP mixed news on monday morning, enjoy. Take advantage of the new QBL-service on Facebook - ask questions etc to management.
https://www.facebook.com/queenslandbauxitelimited/ (updated news)
Puff Puff Post (MMJ News) wrote a piece a while ago, worth reading;
https://www.thepuffpuffpost.com/queensland-bauxite-medical-cannabis-pil/ since then things has evolved; products,distribution and impressive network building.
On-line brokers; ;https://www.asx.com.au/asx/research/findABroker.do
Much can be said about QBL - the people they have chosen to collaborate and do deals with says a lot. They don`t put all the eggs in one basket.
With this setup, they are more protected in a new growing sector.
Mrs Feldman has a long history of exceptional deal-making, I think this one has the potential to be her greatest.
QBL 3 month update of MMJ and Hemp incl links.
Targeting Premium DSO Bauxite 2018 and start operations this year.
https://docs.wixstatic.com/ugd/1943b6_8e1d784...012acb.pdf
QBL Quarterly report december 2017; https://www.queenslandbauxite.com/single-post...T-DEC-2017
QBL Emerging as a keyplayer in Medical Cannabis; https://www.queenslandbauxite.com/single-post...abis-scene
January 8, 2018
• VitaCann Pty Ltd (“VitaCann” subsidairy) has signed an exclusive joint venture agreement (the “Joint Venture”) for a World First Pharmaceutical Grade Medical Cannabis Extended Release Pill with Canntab Therapeutics Limited (“Canntab”) of Toronto,Canada.,
Readmore;https://docs.wixstatic.com/ugd/1943b6_c0073175f4c2485eb7de609e622f50ca.pdf
Breakthrough for GMP Quality Medicinal Cannabis
December 11, 2017
The Board at Queensland Bauxite (ASX:QBL) is excited with the recent success and progress of its investment in Medical Cannabis Ltd (“MCL” or “the Company”), particularly as the medicinal focused arm of that Company, Vitacann, has signed a Letter of Intent for a joint venture subject to full documentation with an Israeli recommended group of North American chemists who have put together what we understand to be a world first in the Medical Cannabis industry. Read More;
https://docs.wixstatic.com/ugd/1943b6_6e8e6bb...457cdc.pdf
MCL (subsidiary to QBL), dec 27, Escalates Hemp Seed Production.
https://www.queenslandbauxite.com/single-post...Production
MCL and AEB join to develop Cannabis veterinary medications; The Boards of Queensland Bauxite Limited (ASX:QBL) and Algae.Tec Ltd (ASX:AEB) are delighted to announce a significant Australian ground breaking agreement whereby AEB will exclusively license Medical Cannabis Limited’s Low THC Delta 9 Cannabis cultivars from the uniqu...
https://www.queenslandbauxite.com/single-post...edications
MMJ cannatab delivery from Canada, approval process on the go. Some day in this month QBL will get good news; GMP- certified plant sends the first products ready for the very lucrative PHARMA market.
With approval done we will see a big jump - to be able to deliver a set of various MMJ formulations (GMP/Pharmagrade approved) is BIG. How big is hard to say - revenue will be a way to measure it.
With Commonwealth countries, these products will be available to a big market. Australia, Canada and UK is main markets with a demand and equal laws regarding MMJ goverment regulations.
There targeting of neighbour Asia next door will be a gamechanger - key (if plans workout); the MMJ producer who gets the lionpart there... since Australia already export to Asia with a long established tradition, it can be a advantage to the North-american competion (diversify).
Politically US has lost some good-will since Mr Trump has said some hard words towards some of the Asian countries - he accuse some of them why US has a tough time within the trading area etc.
https://docs.wixstatic.com/ugd/1943b6_9a2f1ccc39554b11917750e578545fad.pdf
More importantly; QBL will be first out with this new pharma option.
QBL.AX is the ticker. (see board further info and US/Israel-Connection)
OGRMF "Award Winning Hidden Gem OrganiGram" https://ih.advfn.com/p.php?pid=nmona&article=76221056
#RSII: Break out #1 in procress...:-} 0.013... Monday could be 0.016- 0.019...
Ya I just noticed that. I've been without a computer for almost 3 weeks and busy with my Biz as Jan is our busiest month of the year
$PMCB PharmaCyte Biotech Appoints Dr. Mark Rabe Director of Cannabis Program Development PMCB
LAGUNA HILLS, Calif., April 03, 2017 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced the appointment of Mark L. Rabe, MD, as Director of Cannabis Program Development. In his new role, Dr. Rabe will be tasked with leading strategic planning, management and development of PharmaCyte’s Cell-in-a-Box® cannabinoid-based therapy, which is currently in the preclinical research phase. He will also provide operational support to the Chief Executive Officer and executive management team. Dr. Rabe will continue as a member of PharmaCyte’s Medical and Scientific Advisory Board.
PharmaCyte has a license to utilize the Cell-in-a-Box® technology with cannabinoids (constituents of Cannabis) to treat diseases and their related symptoms. PharmaCyte’s “Cannabis Therapy Program” is currently focused on bio-engineering a human cell line that is suitable for Cell-in-a-Box® live-cell encapsulation and capable of producing an enzyme to convert a cannabinoid “prodrug” into its active cancer-killing form. This research seeks to leverage the documented anti-cancer properties of cannabinoid molecules, such as THC (tetrahydrocannabinol) and CBD (cannabidiol).
“We are very pleased to expand Dr. Rabe’s presence at PharmaCyte,” commented PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner. “Dr. Rabe has been superlative in his role as a member of our Medical and Scientific Advisory Board, and now he will be leading our efforts to develop and/or license a marketable Cell-in-a-Box®/cannabinoid therapy. His impressive background in operations, management and educational content development--in addition to his experience as a physician--will also be quite helpful in our planned pivotal clinical trial involving locally-advanced, non-metastatic pancreas cancer.”
Dr. Rabe has worked with PharmaCyte since 2013, when he was appointed as founding member and Chairman of the Medical and Scientific Advisory Board. In this role, he was instrumental in building the Board, designing PharmaCyte’s cannabinoid-based therapy and establishing PharmaCyte’s current Cannabis research program with the University of Northern Colorado. In his new role, Dr. Rabe will assume management of the Cannabis Therapy Program, with the goal of developing a marketable product. With broad experience in business operations, Dr. Rabe will also assist the company in a variety of other areas.
Dr. Rabe’s professional background spans three decades, during which time he has worked as a highly regarded clinical physician, founded and grown several successful healthcare-related businesses, served as Chief Medical Officer of the largest network of physician-owned alternative care centers in the country and served as Medical Director of an e-Learning company that developed educational content for MDs and PhDs at major pharmaceutical companies, such as Eli Lilly, Celgene, Genentech, Amgen and others. Dr. Rabe has also delivered numerous scientific presentations and has served as a Superior Court-approved expert witness in the emerging area of cannabinoid medicine.
Dr. Rabe attended Northwestern University Medical School and he is a diplomate of the American Board of Integrative Holistic Medicine (ABIHM). He received his undergraduate training at Benedictine University, where he earned a summa cum laude degree in biochemistry. Dr. Rabe’s integrative holistic medical practice, Centric Wellness, is in San Diego, California.
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company developing therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed. PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. These encapsulated cells are implanted as close to the patient’s cancerous tumor as possible. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide flows through the encapsulated cells, they act as an artificial liver and activate the chemotherapy drug at the source of the cancer. This “targeted chemotherapy” has proven effective and safe to use in past clinical trials and results in no side effects.
In addition to developing a novel therapy for cancer, PharmaCyte is developing a treatment for Type 1 diabetes and insulin-dependent Type 2 diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology. Once the encapsulated cells are implanted in a diabetic patient they will function as a “bio-artificial pancreas” for purposes of insulin production.
Safe Harbor
This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook" and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement because of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements due to the impact of numerous risk factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.
More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. It can also be obtained by contacting Investor Relations.
Contact:
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: Info@PharmaCyte.com
http://globenewswire.com/news-release/2017/04/03/953603/0/en/PharmaCyte-Biotech-Appoints-Dr-Mark-Rabe-Director-of-Cannabis-Program-Development.html
#RSII: Getting real close to a major breakout...:-}
http://www.risingbiosciences.com/
https://twitter.com/RisingIndiaUSA
http://www.nasdaq.com/press-release/rising-biosciences-inc-develops-groundbreaking-oral-thccbd-delivery-capsule-cannophen-nears-20180118-00670
#CANNABIS NATION: NATIONALLY LEGAL 2018..:-}------>
House Democrats introduce a bill to legalize marijuana and provide 'restorative justice' to communities impacted by the war on drugs
https://www.leafly.com/news/politics/lee-khanna-sponsor-house-version-of-the-marijuana-justice-act
Lee & Khanna Sponsor House Version of the Marijuana Justice Act
http://www.businessinsider.com/marijuana-justice-act-marijuana-legalization-bill-introduced-in-house-2018-1
The Marijuana Justice Act, which Booker introduced in the Senate last August, would end federal cannabis prohibition and help correct decades of injustice surrounding the discriminatory enforcement of marijuana criminalization laws in the United States.
Rep. Barbara Lee (D-CA) and Rep. Ro Khanna (D-CA) today introduced the House version of the Marijuana Justice Act, the companion bill to Sen. Cory Booker’s legislation, S. 1689. The Marijuana Justice Act, which Booker introduced in the Senate last August, would end federal cannabis prohibition and help correct decades of injustice surrounding the discriminatory enforcement of marijuana criminalization laws in the United States.
Booker’s bill would get the federal government out of the prohibition game by declaring that the Controlled Substances Act would no longer apply to cannabis.
The bill would not declare marijuana legal in all 50 states. It would simply remove federal illegality and allow each state to regulate cannabis in its own way. States with criminal penalties for cannabis would keep those laws, at least until voters or legislators decided to change them. States with legal regulated cannabis systems would be allowed to continue without the threat of federal interference.
The bill would also use federal funds to encourages states to change their cannabis laws if those laws are shown to have a disproportionate effect on low-income individuals or people of color. Most studies on the issue have shown that those disproportionate effects happen in every state. The bill also includes provisions for expungement of marijuana-related convictions, and a community reinvestment fund for communities most impacted by the war on drugs and the prohibition of cannabis.
“This legislation will end this destructive war on drugs,” Rep. Lee said this afternoon. “Here on the first day, we have 12 co-signers in the House. Which is really remarkable.”
“This bill is really an essential step in correcting the injustices of the war on drugs,” she added.
Booker Bill Finally Getting Traction
Booker’s bill has suffered from a bout of loneliness since its introduction last year. Until recently only one senator—Oregon Democrat Ron Wyden—had come aboard as a co-sponsor. In the wake of California’s adult-use system opening on Jan. 1, and Attorney General Jeff Sessions’ rescission of the Cole memo, a flurry of new bills and a renewed interest in legalization have taken hold on Capitol Hill.
“We’re seeing this rush of enthusiasm [for legalization], from California to New Jersey,” Booker said. “But it’s hypocritical and destructive if you don’t legalize while trying to undue the damage done by the war on drugs.”
Lee, who introduced a separate measure to prevent enforcement of federal laws in legal states last week, spoke about the “devastating consequences” of Sessions’ removal of the Cole memo guidelines.
We Know Who Suffers in the War on Drugs’
“We know who’s most likely to suffer from a revival of the war on drugs,” she said, referring to disadvantaged neighborhoods and people of color. “The Trump administration has made a major miscalculation,” she said, in attempting to revive the failed drug policies of the 1980s.
Rep. Khanna, whose district includes much of California’s Silicon Valley, addressed the economic issues covered in the bill. “The estimates are that the [nationwide] legalization of marijuana would result in a $40 billion industry, with nearly 1 million jobs and a tax base of $7 billion. That would more than cover the $500 million [in federal incentives and programs] in this bill. It’s a net gain.”
“But the economic impact is so much broader than just that $40 billion industry,” Khanna said. “We’re giving people a real second chance by getting rid of that criminal past that is stifling their future.”
STGZ went crazy today! Wow.
OGMRF OrganiGram https://www.civilized.life/articles/organigram-indoor-cannabis-production/ In Canada TSXV:OGI
Thanks to our friend excboe for sharing this article:)
$GEVO Rodman & Renshaw Gives Gevo $12 Price Target, Reflects On Progress https://www.benzinga.com/analyst-ratings/analyst-color/17/01/8903982/rodman-renshaw-gives-gevo-12-price-target-reflects-on-pr
Thanks, I'll have a look:)
Merry Christmas to all buds here at the exchange
$SIPC on the rise! Only publicly traded hemp and soon to be CBD beer company on the market. Breaking into the California market in 2018!!
ASTI Yahoo Finance has a 1 Year price target on Ascent Solar $ASTI not for $.03 but for $3.00 check it out > https://finance.yahoo.com/quote/asti?ltr=1
Three Canadian Cannabis Awards including Top Sativa Flower of 2017 http://ih.advfn.com/p.php?pid=nmona&article=76221056
TSXV:OGI or US OGRMF
Followers
|
44
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1969
|
Created
|
09/06/14
|
Type
|
Free
|
Moderator sam1933 | |||
Assistants Swimmingly Captainandy birdys3333 Hunchbackgeek $Pistol Pete$ |
Apps *Charts* *State Laws* *Marijuana News* *Social Media news* *AND MUCH MORE!!!!!* <<<===================>>> |
Legal Medical Marijuana States and DC
|
Marijuana Handbook | iSmoke: Weed HD - Free | MyWeed - Grow Weed | Weed Farmer | Marijuana Facts |
Weed HD Wallpaper | Ganja Farmer - Weed empire | Pot Farm - Grass Roots | Joint 4 Dummies | Marijuana Live Wallpaper HD |
Marijuana Index | Marijuana Index | Marijuana Index |
II. Details by State | III. Sources |
$BAYP | $BCAP |
$ENDO | |||||
$FWDG | $GARB |
$GRPS | $GSML | $GERS | |||
$KNSC | $ITNS | ||||
$INMG |
$PMBS |
Feel free to drop suggestions of players in this industry we may have missed and we will add them to the master listing here
<<<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>>>
food storage for emergencies with 30 years shelf life
***BUD eXGANGE - PICKS for January*** Ticker w/STARS: (1=33.3-50% GAIN) | 5 = 1 Blue THE BEST PERFORMERS FOR JANUARY: $ICNB Iconic Brands Inc (PL)-UP 1,681.25% $MKAU Mk Automotive, Inc. (PL)-UP 684.54% $MJTK Cannasys, Inc. (PC)-UP 495.52% $USMJ N.A Cannabis Holdings Inc -UP 433.33% $BABL Buildablock Corp. (PN)-UP 175.00% $MFST Medifirst Solutions Inc. (QB) - UP 170.97% $CGRA Cgrowth Capital, Inc. (PC) -UP 168.00% $SIPC Sipp Industries, Inc. (PC)- 124% $GDGI Greenway Design Group, Inc. (PN) - UP 100% $GRAS Greenfield Farms Food, Inc. (PC) - UP 100% $SGBY Signal Bay, Inc (QB) - UP 76.4% $NGCG New Generation Consumer Group, Inc. (PC)- UP62% $ERBB American Green, Inc. (PC) - UP 62% BIG THANKS TO ALL MEMBERS FOR PARTICIPATION!!! 1. 'birdys3333' - $BABL @ .003 High 0.0082 2. 'sam1933' - $GDGI @ .0001 High 0.002 3. 'Swimmingly' - $BIEL @ .0004 High 0.0004 4. $Pistol Pete$' - $MFST @ .0031 High 0.0084 5. 'Hunchbackgeek' - $SIPC @ .0049 High 0.011 6. 'abe01' - $UNGS @ .0002 High 0.0002 7. 'Liuhisn' - $USMJ @ .0003 High 0.0016 8. 'RookieStockPicker' - $NGCG @ .0015 High 0.0025 9. 'gh0st' - $GRAS @ .0001 High 0.0002 10. 'threewheeler' - $MJTK @ .0021 High 0.0124 11. 'goodnews1' - $AGSTF @ .256 High 0.262 12. 'initforthemoney' - $CHIT @ .0025 High 0.0033 13. 'Michel' - $ERBB @ .0018 High 0.0029 14. 'steam train' - $MKAU @ .0031 High 0.0234 15. 'Elcappy1' - $CGRA @ .0144 High 0.022 16. 'DD_dempsey' - $ICNB @ .0016 High 0.0285 17. 'Goodbuddy' - $SGBY @ .0167 High 0.02945 Best trading to all! sam1933 TRACK YOUR FVT. PICK HERE->BUD-X PORTFOLIO FOR JAN Kindly review and let me know if any changes are required. —————————————————— BABL GDGI BIEL MFST SIPC UNGS USMJ NGCG GRAS MJTK AGSTF CHIT ERBB MKAU CGRA ICNB SGBY
|
------------------------------------------------------
follow
favorites:
- FEATURE HISTORIANS CREATURES HIGHLIGHTS:
MICK AND FRIENDS STOCK PICKS" BOARD !!!:
FORUM FOR ALL STOCKS
- STOCKGOODIES PLAYS OF THE WEEK
$$$$$$$~MARIJUANA~ PLAYS~&~BIG~MOMO/PROMO PLAYS~$$$$$$$
STOCKGOODIES PLAYS OF THE WEEK
BB's Stock Haven |
Posts Today
|
0
|
Posts (Total)
|
1969
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |